Zyvox Suspension
30/06/10
Generic Name: Linezolid (lin-AYZ-oh-lid)
Brand Name: Zyvox
Zyvox Suspension is used for:
Treating adults with certain serious bacterial infections that are often resistant to other antibiotics.
Zyvox Suspension is an oxazolidinone antibiotic. It works by interfering with the production of proteins needed by bacteria to grow.
Do NOT use Zyvox Suspension if:
- you are allergic to any ingredient in Zyvox Suspension
- you are taking an amphetamine (eg, dextroamphetamine), certain anorexiants (eg, phentermine), buspirone, a catechol-O-methyltransferase (COMT) inhibitor (eg, entacapone), levodopa, meperidine, a sympathomimetic (eg, albuterol, dopamine, epinephrine, pseudoephedrine), tetrabenazine, or a triptan (eg, sumatriptan)
- you are taking or have taken certain anorexiants (eg, sibutramine), apraclonidine, bupropion, cyclobenzaprine, a monoamine oxidase inhibitor (MAOI) (eg, phenelzine), a norepinephrine reuptake inhibitor (eg, atomoxetine), a serotonin-norepinephrine reuptake inhibitor (SNRI) (eg, duloxetine), a serotonin reuptake inhibitor (eg, paroxetine), a tetracyclic antidepressant (eg, maprotiline), or a tricyclic antidepressant (eg, amitriptyline) within the past 14 days
Contact your doctor or health care provider right away if any of these apply to you.
Before using Zyvox Suspension:
Some medical conditions may interact with Zyvox Suspension. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:
- if you are pregnant, planning to become pregnant, or are breast-feeding
- if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement
- if you have allergies to medicines, foods, or other substances
- if you have a history of high blood pressure, kidney problems, eye or vision problems, bone marrow problems, low blood cell or platelet levels, an adrenal gland tumor (pheochromocytoma), carcinoid syndrome, severe liver problems, seizures, an overactive thyroid, or phenylketonuria
- if you have a prolonged infection that has been previously treated with another antibiotic medicine
- if you are taking any medicine for depression
Some MEDICINES MAY INTERACT with Zyvox Suspension. Tell your health care provider if you are taking any other medicines, especially any of the following:
- Amphetamines (eg, dextroamphetamine), certain anorexiants (eg, phentermine, sibutramine), apraclonidine, ginseng, meperidine, sympathomimetics (eg, albuterol, dopamine, epinephrine, pseudoephedrine), or tryptophan because the risk of serious side effects, including severe headache, fever, or high blood pressure, may be increased
- Bupropion, busporine, catechol-O-methyltransfirase (COMT) inhibitors (eg, entacapone), levodopa, MAOIs (eg, phenelzine), norepinephrine reuptake inhibitors (eg, atomoxetine), propoxyphene, SNRIs (eg, duloxetine ), tetrabenazine, tetracyclic antidepressants (eg, maprotiline), tricyclic antidepressants (eg, amitriptyline), or triptans (eg, sumatriptan) because the risk of serious side effects, including severe fever, mental or mood changes, or muscle problems, may be increased
- Carbamazepine, barbiturates (eg, phenobarbital), hydantoins (eg, phenytoin), or rifamycins (eg, rifampin) because they may decrease Zyvox Suspension’s effectiveness
This may not be a complete list of all interactions that may occur. Ask your health care provider if Zyvox Suspension may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.
How to use Zyvox Suspension:
Use Zyvox Suspension as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- Take Zyvox Suspension by mouth with or without food. If stomach upset occurs, take with food to reduce stomach irritation.
- Gently mix before each dose by turning the bottle upside-down 3 to 5 times. Do not shake Zyvox Suspension.
- Use a measuring device marked for medicine dosing. Ask your pharmacist for help if you are unsure of how to measure your dose.
- To clear up your infection completely, take Zyvox Suspension for the full course of treatment. Keep taking it even if you feel better in a few days.
- If you miss a dose of Zyvox Suspension, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.
Ask your health care provider any questions you may have about how to use Zyvox Suspension.
Important safety information:
- Zyvox Suspension may cause dizziness. This effect may be worse if you take it with alcohol or certain medicines. Use Zyvox Suspension with caution. Do not drive or perform other possibly unsafe tasks until you know how you react to it.
- Be sure to use Zyvox Suspension for the full course of treatment. If you do not, the medicine may not clear up your infection completely. The bacteria could also become less sensitive to this or other medicines. This could make the infection harder to treat in the future.
- Long-term or repeated use of Zyvox Suspension may cause a second infection. Tell your doctor if signs of a second infection occur. Your medicine may need to be changed to treat this.
- Mild diarrhea is common with antibiotic use. However, a more serious form of diarrhea (pseudomembranous colitis) may rarely occur. This may develop while you use the antibiotic or within several months after you stop using it. Contact your doctor right away if stomach pain or cramps, severe diarrhea, or bloody stools occur. Do not treat diarrhea without first checking with your doctor.
- Eating foods high in tyramine (eg, aged cheeses, red wines, beer, certain meats and sausages, liver, sour cream, soy sauce, raisins, bananas, avocados) while you use an MAOI may cause severe high blood pressure. This could occur for up to 2 weeks after you stop taking an MAOI. Do not eat foods high in tyramine while you take Zyvox Suspension. Ask your health care provider for a complete list of foods you should avoid. Seek medical attention at once if symptoms of severe high blood pressure occur. These may include severe headache, fast or irregular heartbeat, sore or stiff neck, nausea, vomiting, sweating, enlarged pupils, or sensitivity to light.
- Zyvox Suspension may reduce the number of clot-forming cells (platelets) in your blood. Avoid activities that may cause bruising or injury. Tell your doctor if you have unusual bruising or bleeding. Tell your doctor if you have dark, tarry, or bloody stools.
- Zyvox Suspension only works against bacteria; it does not treat viral infections (eg, the common cold).
- Lactic acidosis has occurred with the use of Zyvox Suspension. Contact your doctor if you have severe, persistent nausea, vomiting, stomach pain, or unusual tiredness or weakness.
- Serious eye problems (eg, peripheral and optic neuropathy) have occurred with the use of Zyvox Suspension. Contact your doctor if you experience vision changes (eg, decreased or blurred vision, changes in color vision, loss of vision).
- Phenylketonuria patients – Zyvox Suspension contains phenylalanine. If you must have a diet that is low in phenylalanine, talk with your doctor or pharmacist.
- Lab tests, including complete blood cell counts and eye exams, may be performed while you use Zyvox Suspension. These tests may be used to monitor your condition or check for side effects. Be sure to keep all doctor and lab appointments.
- Zyvox Suspension should be used with extreme caution in CHILDREN; safety and effectiveness in children have not been confirmed.
- PREGNANCY and BREAST-FEEDING: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Zyvox Suspension while you are pregnant. It is not known if Zyvox Suspension is found in breast milk. If you are or will be breast-feeding while you use Zyvox Suspension, check with your doctor. Discuss any possible risks to your baby.
Possible side effects of Zyvox Suspension:
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:
Bad taste in mouth; constipation; diarrhea; dizziness; headache; nausea; trouble sleeping; vomiting.
Seek medical attention right away if any of these SEVERE side effects occur:
Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue; unusual hoarseness); agitation; bloody stools; bloody vomit; chills, fever, or sore throat; confusion; exaggerated reflexes; excitation; fast heartbeat; loss of coordination; mental or mood changes; muscle spasms; prolonged or repeated nausea or vomiting; red, swollen, peeling, or blistered skin; seizures; severe or continuing diarrhea; stomach pain/cramps; sweating; swelling of the hands or feet; tingling or numbness of the hands or feet; unusual bleeding or bruising; unusual tiredness or weakness; vaginal irritation or unusual discharge; vision changes; white patches in the mouth.
This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects at http://www.fda.gov/medwatch.
If OVERDOSE is suspected:
Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (http://www.aapcc.org), or emergency room immediately.
Proper storage of Zyvox Suspension:
Store Zyvox Suspension at 77 degrees F (25 degrees C). Brief storage at temperatures between 59 and 86 degrees F (15 and 30 degrees C) is permitted. Store away from heat, moisture, and light. Do not store in the bathroom. Keep the bottle tightly closed. Discard any unused medicine 21 days after mixing. Keep Zyvox Suspension out of the reach of children and away from pets.
General information:
- If you have any questions about Zyvox Suspension, please talk with your doctor, pharmacist, or other health care provider.
- Zyvox Suspension is to be used only by the patient for whom it is prescribed. Do not share it with other people.
- If your symptoms do not improve or if they become worse, check with your doctor.
This information is a summary only. It does not contain all information about Zyvox Suspension. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.
Zytopic
30/06/10
Generic Name: triamcinolone (Topical application route)
trye-am-SIN-oh-lone a-SEET-oh-nide
Commonly used brand name(s):
In the U.S.
- Aristocort A
- Cinolar
- Kenalog
- Triacet
- Triamcot
- Triderm
- Zytopic
In Canada
- Aristocort C Concentrate
- Aristocort D Dilute
- Aristocort R Ointment Regular
- Aristocort R Regular
- Kenalog Cream
- Kenalog Ointment
- Kenalog Spray
- Triaderm Mild Cream
- Triaderm Mild Ointment
- Triaderm Regular Cream
- Triaderm Regular Ointment
- Trianide Mild-Cream
Available Dosage Forms:
- Cream
- Lotion
- Spray
- Ointment
Therapeutic Class: Corticosteroid, Intermediate
Pharmacologic Class: Triamcinolone
Uses For Zytopic
Triamcinolone topical is used to help relieve redness, itching, swelling, or other discomfort caused by skin conditions. This medicine is a corticosteroid (cortisone-like medicine or steroid).
This medicine is available only with your doctor’s prescription.
Before Using Zytopic
In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:
Allergies
Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.
Pediatric
Appropriate studies performed to date have not demonstrated pediatric-specific problems that would limit the usefulness of triamcinolone topical in the pediatric population. However, because of this medicine’s toxicity, it should be used with caution. Children may absorb large amounts through the skin, which can cause serious side effects. If your child is using this medicine, follow your doctor’s instructions very carefully.
Geriatric
No information is available on the relationship of age to the effects of triamcinolone topical in geriatric patients.
Interactions with Medicines
Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. Tell your healthcare professional if you are taking any other prescription or nonprescription (over-the-counter [OTC]) medicine.
Interactions with Food/Tobacco/Alcohol
Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco.
Other Medical Problems
The presence of other medical problems may affect the use of this medicine. Make sure you tell your doctor if you have any other medical problems, especially:
- Cushing’s syndrome (adrenal gland disorder) or
- Diabetes or
- Hyperglycemia (high blood sugar) or
- Intracranial hypertension (increased pressure in the head)—Use with caution. May make these conditions worse.
- Infection of the skin at or near the place of application or
- Large sores, broken skin, or severe skin injury at the place of application—The chance of side effects may be increased.
Proper Use of triamcinolone
This section provides information on the proper use of a number of products that contain triamcinolone. It may not be specific to Zytopic. Please read with care.
It is very important that you use this medicine only as directed by your doctor. Do not use more of it, do not use it more often, and do not use it for a longer time than your doctor ordered. To do so may cause unwanted side effects or skin irritation.
This medicine is for use on the skin only. Do not get it in your eyes. Do not use it on skin areas that have cuts, scrapes, or burns. If it does get on these areas, rinse it off right away with water.
If you or your child are using the spray form on or near the face, protect your nose to avoid breathing it in and make sure that your eyes are covered.
This medicine should only be used for skin conditions that your doctor is treating. Check with your doctor before using it for other conditions, especially if you think that a skin infection may be present. This medicine should not be used to treat certain kinds of skin infections or conditions, such as severe burns.
To use:
- Wash your hands with soap and water before and after using this medicine.
- Apply a thin layer of this medicine to the affected area of the skin. Rub it in gently.
- Do not bandage or otherwise wrap the skin being treated unless directed to do so by your doctor.
- If the medicine is applied to the diaper area of an infant, do not use tight-fitting diapers or plastic pants unless directed to do so by your doctor.
- If your doctor ordered an occlusive dressing or airtight covering to be applied over the medicine, make sure you know how to apply it. Occlusive dressings increase the amount of medicine absorbed through your skin, so use them only as directed. If you have any questions about this, check with your doctor.
Dosing
The dose of this medicine will be different for different patients. Follow your doctor’s orders or the directions on the label. The following information includes only the average doses of this medicine. If your dose is different, do not change it unless your doctor tells you to do so.
The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.
- For redness, itching, and swelling of the skin:
- For topical dosage forms (cream, lotion, and ointment):
- Adults—Apply to the affected area of the skin two to four times per day.
- Children—Apply to the affected area of the skin two to four times per day.
- For topical dosage form (aerosol spray):
- Adults—Spray to the affected area of the skin three to four times per day.
- Children—Spray to the affected area of the skin three to four times per day.
- For topical dosage forms (cream, lotion, and ointment):
Missed Dose
If you miss a dose of this medicine, apply it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule.
Storage
Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing.
Store the canister at room temperature, away from heat and direct light. Do not freeze. Do not keep this medicine inside a car where it could be exposed to extreme heat or cold. Do not poke holes in the canister or throw it into a fire, even if the canister is empty.
Keep out of the reach of children.
Do not keep outdated medicine or medicine no longer needed.
Ask your healthcare professional how you should dispose of any medicine you do not use.
Precautions While Using Zytopic
It is very important that your doctor check the progress of you or your child at regular visits for any unwanted effects that may be caused by this medicine.
If your or your child’s symptoms do not improve within a few days, or if they become worse, check with your doctor.
Using too much of this medicine or using it for a long time may increase your risk of having adrenal gland problems. The risk is greater for children and patients who use large amounts for a long time. Talk to your doctor right away if you or your child have more than one of these symptoms while you are using this medicine: blurred vision; dizziness or fainting; a fast, irregular, or pounding heartbeat; increased thirst or urination; irritability; or unusual tiredness or weakness.
Stop using this medicine and check with your doctor right away if you or your child have a skin rash, burning, stinging, swelling, or irritation on the skin.
Do not use cosmetics or other skin care products on the treated areas.
Zytopic Side Effects
Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur:
Incidence not known
- Blistering, burning, crusting, dryness, or flaking of the skin
- irritation
- itching, scaling, severe redness, soreness, or swelling of the skin
- redness and scaling around the mouth
- thinning of the skin with easy bruising, especially when used on the face or where the skin folds together (e.g. between the fingers)
Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Incidence not known
- Acne or pimples
- burning and itching of the skin with pinhead-sized red blisters
- burning, itching, and pain in hairy areas, or pus at the root of the hair
- increased hair growth on the forehead, back, arms, and legs
- lightening of normal skin color
- lightening of treated areas of dark skin
- reddish purple lines on the arms, face, legs, trunk, or groin
- softening of the skin
Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.
Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.
The information contained in the Thomson Reuters Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.
The use of the Thomson Reuters Healthcare products is at your sole risk. These products are provided “AS IS” and “as available” for use, without warranties of any kind, either express or implied. Thomson Reuters Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON REUTERS HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Reuters Healthcare does not assume any responsibility or risk for your use of the Thomson Reuters Healthcare products.
Zyvox
30/06/10
Generic name: Linezolid
Brand names: Zyvox
Why is Zyvox prescribed?
Zyvox is a member of a new class of antibiotics called oxazolidinones. It is used to treat certain types of pneumonia, some forms of skin infection, and infections involving certain strains of a germ called Enterococcus faecium.
Most important fact about Zyvox
Antibiotic treatment can cause a type of diarrhea that, in rare cases, becomes extremely severe. If you develop diarrhea after starting Zyvox, be sure to notify your doctor immediately.
If you need to take Zyvox for more than two weeks, your doctor will perform blood tests to check for blood abnormalities. Blood tests are also needed if you tend to bleed easily or are taking medications that increase your chance of bleeding.
Zyvox could cause a very rare—but potentially fatal—side effect known as lactic acidosis, especially if the treatment lasts longer than the recommended 28 days. It is caused by a buildup of lactic acid in the blood. Lactic acidosis is a medical emergency that must be treated in a hospital. Notify your doctor immediately if you experience repeated nausea and vomiting or any of the following:
- Symptoms of lactic acidosis may include:
Dizziness, extreme weakness or tiredness, light-headedness, low body temperature, rapid breathing or trouble breathing, sleepiness, slow or irregular heartbeat, unexpected or unusual stomach discomfort, unusual muscle pain
How should you take Zyvox?
Zyvox should be taken twice a day, every 12 hours, until the prescription is finished. Do not stop taking the medicine when you start to feel better. If you discontinue it too soon, surviving germs may cause a relapse. Zyvox may be taken with or without food.
If you are taking the liquid formulation of Zyvox, gently mix it before each use by turning the bottle upside down and upright 3 to 5 times. Do not shake the bottle.
Your doctor will only prescribe Zyvox to treat a bacterial infection; it will not cure a viral infection, such as the common cold. It’s important to take the full dosage schedule of Zyvox, even if you’re feeling better in a few days. Not completing the full dosage schedule may decrease the drug’s effectiveness and increase the chances that the bacteria may become resistant to Zyvox and similar antibiotics.
- If you miss a dose…
Take it as soon as you remember. If it is almost time for your next dose, skip the one you missed and go back to your regular schedule. Never take 2 doses at the same time.
- Storage instructions…
Both Zyvox tablets and Zyvox liquid can be stored at room temperature. Keep the bottles tightly closed and protect from light and moisture. The liquid formulation should be used within 21 days.
What side effects may occur?
Side effects cannot be anticipated. If any develop or change in intensity, inform your doctor as soon as possible. Only your doctor can determine if it is safe for you to continue taking Zyvox.
- Side effects reported in adults may include:
Diarrhea, headache, nausea, vomiting
- Side effects reported in children may include:
Anemia, blood infection, diarrhea, fever, rash, upper respiratory infection, vomiting
Why should Zyvox not be prescribed?
If Zyvox gives you an allergic reaction, you won’t be able to use it.
Special warnings about Zyvox
Let the doctor know if you have high blood pressure. Zyvox has not been tested under these conditions.
If you’re taking Zyvox with a class of antidepressants known as selective serotonin reuptake inhibitors (SSRIs), there is a chance of developing serotonin syndrome. Symptoms include euphoria, drowsiness, rapid muscle contraction and relaxation, restlessness, dizziness, sweating, coordination problems, and fever. If you experience these symptoms, seek medical attention immediately.
Vision problems─including blurred vision, change in color perception, and problems with depth perception─may be caused by Zyvox treatment that lasts for more than 28 days. If this occurs, contact your doctor right away.
If you have a condition called phenylketonuria and must avoid the amino acid phenylalanine, it’s important to know that the liquid formulation of Zyvox contains this substance.
Possible food and drug interactions when taking Zyvox
If Zyvox is taken with certain other drugs, the effects of either could be increased, decreased, or altered. It is especially important to check with your doctor before combining Zyvox with the following:
Serotonin-boosting antidepressants
Decongestants
Over-the-counter cold medicines and cough syrups that contain pseudoephedrine
While taking Zyvox, it’s important to avoid eating large amounts of foods that contain a chemical called tyramine. Food products high in tyramine include aged cheese, fermented or air-dried meats such as dry sausage, sauerkraut, soy sauce, red wine, tap beers, and any protein-rich food that has been improperly refrigerated.
Special information if you are pregnant or breastfeeding
Zyvox has not been studied in pregnant women or nursing mothers. Because the possibility of harm to the developing baby has not been ruled out, Zyvox should be used during pregnancy only if the potential benefit outweighs the possible risk. If you wish to breastfeed your infant, discuss your treatment options with your doctor.
Recommended dosage for Zyvox
ADULTS AND ADOLESCENTS 12 AND OLDER
Pneumonia and Complicated Skin Infections
The usual dosage is 600 milligrams every 12 hours for 10 to 14 days.
Uncomplicated Skin Infections
Adults: The usual dosage is 400 milligrams every 12 hours for 10 to 14 days.
Adolescents 12 years and older: The usual dosage is 600 milligrams every 12 hours for 10 to 14 days.
Enterococcus faecium Infections
The usual dosage is 600 milligrams every 12 hours for 14 to 28 days.
CHILDREN (BIRTH TO 11 YEARS OLD)
Pneumonia and Complicated Skin Infections
The usual dosage is 10 milligrams for every 2.2 pounds of body weight taken every 8 hours for 10 to 14 days.
Uncomplicated Skin Infections
Children under 5 years old: The usual dosage is 10 milligrams for every 2.2 pounds of body weight taken every 8 hours for 10 to 14 days.
Children 5 to 11 years old: The usual dosage is 10 milligrams for every 2.2 pounds of body weight taken every 12 hours for 10 to 14 days.
Enterococcus faecium Infections
The usual dosage is 10 milligrams for every 2.2 pounds of body weight taken every 8 hours for 14 to 28 days.
Overdosage
Little is known about the effects of a Zyvox overdose. However, any medication taken in excess can have serious consequences, so if you suspect an overdose, seek medical attention immediately.
Zyrtec-D 12 Hour
30/06/10
Generic Name: Cetirizine/Pseudoephedrine (seh-TIH-rih-zeen/SUE-doe-eh-FED-rin)
Brand Name: Zyrtec-D 12 Hour
Zyrtec-D 12 Hour is used for:
Relieving nasal and non-nasal symptoms associated with seasonal and perennial allergies such as watery or itchy eyes, runny nose, sneezing, and stuffy nose.
Zyrtec-D 12 Hour is a decongestant (pseudoephedrine) and antihistamine (cetirizine) combination. It works by blocking a chemical in the body, histamine, which causes allergy symptoms. It also shrinks swollen nasal passages, which relieves nasal congestion.
Do NOT use Zyrtec-D 12 Hour if:
- you are allergic to any ingredient in Zyrtec-D 12 Hour
- you have narrow-angle glaucoma, severe difficulty urinating, very high blood pressure, or severe heart or blood vessel disease
- you are currently taking or have taken furazolidone or a monoamine oxidase (MAO) inhibitor (eg, phenelzine) within the last 14 days
Contact your doctor or health care provider right away if any of these apply to you.
Before using Zyrtec-D 12 Hour:
Some medical conditions may interact with Zyrtec-D 12 Hour. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:
- if you are pregnant, planning to become pregnant, or are breast-feeding
- if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement
- if you have allergies to medicines, foods, or other substances
- if you have diabetes, difficulty urinating due to an enlarged prostate, heart or kidney problems, an overactive thyroid, glaucoma, or high blood pressure
Some MEDICINES MAY INTERACT with Zyrtec-D 12 Hour. Tell your health care provider if you are taking any other medicines, especially any of the following:
- Furazolidone or MAO inhibitors (eg, phenelzine) because they can cause serious, sometimes fatal, reactions. Do not take MAO inhibitors within 2 weeks of taking Zyrtec-D 12 Hour.
- Certain stimulants (albuterol, amphetamine), digitalis (eg, digoxin), or droxidopa because toxic effects on the heart may occur
- Urinary alkalinizers (eg, sodium bicarbonate) because it may increase the actions and side effects of Zyrtec-D 12 Hour
- Bromocriptine or certain antihypertensives (guanethidine, methyldopa, mecamylamine, reserpine) because their effectiveness may be decreased by Zyrtec-D 12 Hour
This may not be a complete list of all interactions that may occur. Ask your health care provider if Zyrtec-D 12 Hour may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.
How to use Zyrtec-D 12 Hour:
Use Zyrtec-D 12 Hour as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- Zyrtec-D 12 Hour may be taken with or without food.
- Swallow whole. Do not crush, break, or chew before swallowing.
- If you miss a dose of Zyrtec-D 12 Hour, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.
Ask your health care provider any questions you may have about how to use Zyrtec-D 12 Hour.
Important safety information:
- Zyrtec-D 12 Hour may cause dizziness or drowsiness. Do not drive, operate machinery, or do anything else that could be dangerous until you know how you react to Zyrtec-D 12 Hour. Using Zyrtec-D 12 Hour alone, with certain other medicines, or with alcohol may lessen your ability to drive or to perform other potentially dangerous tasks.
- Avoid drinking alcohol or taking other medicines that cause drowsiness (eg, sedatives, tranquilizers) while taking Zyrtec-D 12 Hour. Zyrtec-D 12 Hour will add to the effects of alcohol and other depressants. Ask your pharmacist if you have questions about which medicines are depressants.
- If you have trouble sleeping, ask your doctor or pharmacist about the best time to take Zyrtec-D 12 Hour.
- Zyrtec-D 12 Hour may interfere with allergy test results. Check with your doctor for more information.
- Diabetes patients – Zyrtec-D 12 Hour may affect your blood sugar level. Your doctor may need to change the amount of diabetes medicine you are taking.
- Use Zyrtec-D 12 Hour with caution in the ELDERLY because they may be more sensitive to its effects, especially drowsiness.
- Zyrtec-D 12 Hour is not recommended for use in children younger than 12 years of age. Safety and effectiveness in the age group have not been confirmed.
- PREGNANCY and BREAST-FEEDING: If you become pregnant, discuss with your doctor the benefits and risks of using Zyrtec-D 12 Hour during pregnancy. Zyrtec-D 12 Hour is excreted in breast milk. Do not breast-feed while taking Zyrtec-D 12 Hour.
Possible side effects of Zyrtec-D 12 Hour:
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:
Dizziness; drowsiness; dry mouth; fatigue; headache; nausea; nervousness; sore throat; trouble sleeping.
Seek medical attention right away if any of these SEVERE side effects occur:
Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); dark urine; difficulty urinating; mental or mood changes; persistent tiredness; seizures; sleeplessness; uncontrolled shaking or tremor; unusually fast/irregular heart rhythm; weakness; yellowing of the eyes or skin.
This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects at http://www.fda.gov/medwatch.
If OVERDOSE is suspected:
Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (http://www.aapcc.org), or emergency room immediately. Symptoms may include confusion; difficulty breathing; hallucinations; irregular or fast heartbeat; loss of consciousness; seizures; severe drowsiness; sleeplessness; tremors.
Proper storage of Zyrtec-D 12 Hour:
Store Zyrtec-D 12 Hour at room temperature, 68 to 77 degrees F (20 to 25 degrees C), in a tightly closed container. Store away from heat, moisture, and light. Do not store in the bathroom. Keep Zyrtec-D 12 Hour out of the reach of children and away from pets.
General information:
- If you have any questions about Zyrtec-D 12 Hour, please talk with your doctor, pharmacist, or other health care provider.
- Zyrtec-D 12 Hour is to be used only by the patient for whom it is prescribed. Do not share it with other people.
- If your symptoms do not improve or if they become worse, check with your doctor.
This information is a summary only. It does not contain all information about Zyrtec-D 12 Hour. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.
Zyrtec-D
30/06/10
Generic Name: cetirizine and pseudoephedrine (se TIR i zeen and SOO doe e FED rin)
Brand Names: All Day Allergy-D, Zyrtec-D
What is Zyrtec-D (cetirizine and pseudoephedrine)?
Cetirizine is an antihistamine that reduces the natural chemical histamine in the body. Histamine can produce symptoms of sneezing, itching, watery eyes, and runny nose.
Pseudoephedrine is a decongestant that shrinks blood vessels in the nasal passages. Dilated blood vessels can cause nasal congestion (stuffy nose).
The combination of cetirizine and pseudoephedrine is used to treat cold or allergy symptoms such as nasal and sinus congestion, sneezing, itching, watery eyes, or runny nose.
Cetirizine and pseudoephedrine may also be used for other purposes not listed in this medication guide.
What is the most important information I should know about Zyrtec-D (cetirizine and pseudoephedrine)?
Do not use this medication if you have used an MAO inhibitor such as isocarboxazid (Marplan), phenelzine (Nardil), rasagiline (Azilect), selegiline (Eldepryl, Emsam), or tranylcypromine (Parnate) within the past 14 days.
You should not use cetirizine and pseudoephedrine if you are allergic to either drug, or if you have narrow-angle glaucoma, severe high blood pressure (hypertension), severe coronary artery disease, if you are unable to urinate, or if you are allergic to hydralazine (Atarax, Vistaril).
Do not use any other over-the-counter cold medication without first asking your doctor or pharmacist. Pseudoephedrine is contained in many medicines available over the counter. If you take certain products together you may accidentally take too much of this drug. Read the label of any other medicine you are using to see if it contains pseudoephedrine.
Cetirizine can cause side effects that may impair your thinking or reactions. Be careful if you drive or do anything that requires you to be awake and alert. Avoid drinking alcohol. It can increase some of the side effects of cetirizine. Call your doctor if your symptoms do not improve, if they get worse, or if you also have a fever.
What should I discuss with my healthcare provider before taking Zyrtec-D (cetirizine and pseudoephedrine)?
Do not use cetirizine and pseudoephedrine if you have used an MAO inhibitor such as isocarboxazid (Marplan), phenelzine (Nardil), rasagiline (Azilect), selegiline (Eldepryl, Emsam), or tranylcypromine (Parnate) within the past 14 days. Serious side effects can occur if you take pseudoephedrine before the MAO inhibitor has cleared from your body. You should not use cetirizine and pseudoephedrine if you are allergic to either drug, or if you have:
-
narrow-angle glaucoma;
-
severe high blood pressure (hypertension);
-
severe coronary artery disease;
-
if you are unable to urinate; or
-
if you are allergic to hydralazine (Atarax, Vistaril).
Ask a doctor or pharmacist about using cetirizine and pseudoephedrine if you have:
-
heart disease, coronary artery disease, high blood pressure, or heart rhythm disorder;
-
diabetes;
-
a thyroid disorder;
-
glaucoma;
-
kidney or liver disease;
-
an enlarged prostate; or
-
problems with urination.
FDA pregnancy category C. It is not known whether cetirizine and pseudoephedrine is harmful to an unborn baby. Before taking this medication, tell your doctor if you are pregnant or plan to become pregnant during treatment. Cetirizine and pseudoephedrine can pass into breast milk and may harm a nursing baby. Do not use this medication without telling your doctor if you are breast-feeding a baby.
Older adults may be more likely to have side effects from cetirizine and pseudoephedrine.
How should I take Zyrtec-D (cetirizine and pseudoephedrine)?
Take this medication exactly as directed on the label, or as prescribed by your doctor. Do not use it in larger amounts or for longer than recommended.
Take one tablet every 12 hours, unless your doctor tells you otherwise. You may take this medication with or without food.
Do not crush, chew, or break an extended-release tablet. Swallow the pill whole. Breaking or opening the pill may cause too much of the medicine to be released at one time. Call your doctor if your symptoms do not improve, if they get worse, or if you also have a fever. Store cetirizine and pseudoephedrine at room temperature away from moisture and heat.
What happens if I miss a dose?
Take the missed dose as soon as you remember. If it is almost time for your next dose, wait until then to take the medicine and skip the missed dose. Do not take extra medicine to make up the missed dose.
What happens if I overdose?
Seek emergency medical attention if you think you have used too much of this medicine.
Overdose symptoms may include feeling restless or nervous, headache, nausea, vomiting, sweating, anxiety, drowsiness, increased thirst, fast or pounding heartbeats, trouble sleeping, or problems with urination.
What should I avoid while taking Zyrtec-D (cetirizine and pseudoephedrine)?
Avoid taking diet pills, caffeine pills, or other stimulants (such as ADHD medications) without your doctor’s advice. Taking a stimulant together with pseudoephedrine can increase your risk of unpleasant side effects.
Do not use any other over-the-counter cold medication without first asking your doctor or pharmacist. Pseudoephedrine is contained in many medicines available over the counter. If you take certain products together you may accidentally take too much of this drug. Read the label of any other medicine you are using to see if it contains pseudoephedrine. Cetirizine can cause side effects that may impair your thinking or reactions. Be careful if you drive or do anything that requires you to be awake and alert. Avoid drinking alcohol. It can increase some of the side effects of cetirizine.
Zyrtec-D (cetirizine and pseudoephedrine) side effects
Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. Stop using this medication and call your doctor at once if you have any of these serious side effects:
-
fast, pounding, or uneven heartbeat;
-
weakness, tremors (uncontrolled shaking), or sleep problems (insomnia);
-
severe restless feeling, hyperactivity;
-
extreme feeling of fear or confusion;
-
increased blood pressure (severe headache, blurred vision, trouble concentrating, chest pain, numbness, seizure);
-
problems with vision; or
-
urinating less than usual or not at all.
Less serious side effects may include:
-
dizziness, drowsiness;
-
tired feeling;
-
dry mouth;
-
nausea, stomach pain, constipation;
-
problems with concentration; or
-
ringing in your ears.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What other drugs will affect Zyrtec-D (cetirizine and pseudoephedrine)?
Tell your doctor if you regularly use other medicines that make you sleepy (such as other cold or allergy medicine, narcotic pain medicine, sleeping pills, muscle relaxers, and medicine for seizures, depression, or anxiety). They can add to sleepiness caused by cetirizine.
Before taking this medication, tell your doctor if you are also using any of the following drugs:
-
digoxin (digitalis, Lanoxin);
-
blood pressure medication, especially methyldopa (Aldomet), mecamylamine (Inversine), or reserpine; or
-
diet pills, stimulants, or ADHD medications.
This list is not complete and there may be other drugs that can interact with cetirizine and pseudoephedrine. Tell your doctor about all your prescription and over-the-counter medications, vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start a new medication without telling your doctor.
Where can I get more information?
- Your pharmacist can provide more information about cetirizine and pseudoephedrine.
- Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed.
- Every effort has been made to ensure that the information provided by Cerner Multum, Inc. (‘Multum’) is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Multum information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Multum does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Multum’s drug information does not endorse drugs, diagnose patients or recommend therapy. Multum’s drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Multum does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Copyright 1996-2006 Cerner Multum, Inc. Version: 4.01. Revision Date: 04/06/2009 12:03:54 PM.
Zyrtec Tablets
30/06/10
Generic Name: cetirizine hydrochloride
Dosage Form: tablets, chewable tablets, syrup
Zyrtec Tablets Description
Cetirizine hydrochloride, the active component of ZYRTEC® tablets and syrup, is an orally active and selective H1-receptor antagonist. The chemical name is (±) – [2- [4- [ (4-chlorophenyl)phenylmethyl] -1- piperazinyl] ethoxy]acetic acid, dihydrochloride. Cetirizine hydrochloride is a racemic compound with an empirical formula of C21H25ClN2O3•2HCl. The molecular weight is 461.82 and the chemical structure is shown below:

Cetirizine hydrochloride is a white, crystalline powder and is water soluble. Zyrtec Tablets are formulated as white, film-coated, rounded-off rectangular shaped tablets for oral administration and are available in 5 and 10 mg strengths. Inactive ingredients are: lactose monohydrate; microcrystalline cellulose; colloidal silicon dioxide; croscarmellose sodium; magnesium stearate; titanium dioxide; hypromellose; and polyethylene glycol.
ZYRTEC chewable tablets are formulated as purple round tablets for oral administration and are available in 5 and 10 mg strengths. Inactive ingredients of the chewable tablets are: acesulfame potassium; artificial grape flavor; betadex, NF; blue dye; colloidal silicon dioxide; lactose monohydrate; magnesium stearate; mannitol; microcrystalline cellulose; natural flavor; red dye (carmine).
ZYRTEC syrup is a colorless to slightly yellow syrup containing cetirizine hydrochloride at a concentration of 1 mg/mL (5 mg/5 mL) for oral administration. The pH is between 4 and 5. The inactive ingredients of the syrup are: banana flavor; glacial acetic acid; glycerin; grape flavor; methylparaben; propylene glycol; propylparaben; sodium acetate; sugar syrup; and water.
Zyrtec Tablets – Clinical Pharmacology
Mechanism of Actions
Cetirizine, a human metabolite of hydroxyzine, is an antihistamine; its principal effects are mediated via selective inhibition of peripheral H1 receptors. The antihistaminic activity of cetirizine has been clearly documented in a variety of animal and human models. In vivo and ex vivo animal models have shown negligible anticholinergic and antiserotonergic activity. In clinical studies, however, dry mouth was more common with cetirizine than with placebo. In vitro receptor binding studies have shown no measurable affinity for other than H1 receptors. Autoradiographic studies with radiolabeled cetirizine in the rat have shown negligible penetration into the brain. Ex vivo experiments in the mouse have shown that systemically administered cetirizine does not significantly occupy cerebral H1 receptors.
Pharmacokinetics
Cetirizine was rapidly absorbed with a time to maximum concentration (Tmax) of approximately 1 hour following oral administration of tablets, chewable tablets or syrup in adults. Comparable bioavailability was found between the tablet and syrup dosage forms. Comparable bioavailability was also found between the ZYRTEC tablet and the ZYRTEC chewable tablet taken with or without water. When healthy volunteers were administered multiple doses of cetirizine (10 mg tablets once daily for 10 days), a mean peak plasma concentration (Cmax) of 311 ng/mL was observed. No accumulation was observed. Cetirizine pharmacokinetics were linear for oral doses ranging from 5 to 60 mg. Food had no effect on the extent of exposure (AUC) of the cetirizine tablet or chewable tablet, but Tmax was delayed by 1.7 hours and 2.8 hours respectively, and Cmax was decreased by 23% and 37%, respectively in the presence of food.
The mean plasma protein binding of cetirizine is 93%, independent of concentration in the range of 25–1000 ng/mL, which includes the therapeutic plasma levels observed.
A mass balance study in 6 healthy male volunteers indicated that 70% of the administered radioactivity was recovered in the urine and 10% in the feces. Approximately 50% of the radioactivity was identified in the urine as unchanged drug. Most of the rapid increase in peak plasma radioactivity was associated with parent drug, suggesting a low degree of first-pass metabolism. Cetirizine is metabolized to a limited extent by oxidative O-dealkylation to a metabolite with negligible antihistaminic activity. The enzyme or enzymes responsible for this metabolism have not been identified.
The mean elimination half-life in 146 healthy volunteers across multiple pharmacokinetic studies was 8.3 hours and the apparent total body clearance for cetirizine was approximately 53 mL/min.
Pharmacokinetic interaction studies with cetirizine in adults were conducted with pseudoephedrine, antipyrine, ketoconazole, erythromycin and azithromycin. No interactions were observed. In a multiple dose study of theophylline (400 mg once daily for 3 days) and cetirizine (20 mg once daily for 3 days), a 16% decrease in the clearance of cetirizine was observed. The disposition of theophylline was not altered by concomitant cetirizine administration.
Pediatric Patients
When pediatric patients aged 7 to 12 years received a single, 5-mg oral cetirizine capsule, the mean Cmax was 275 ng/mL. Based on cross-study comparisons, the weight-normalized, apparent total body clearance was 33% greater and the elimination half-life was 33% shorter in this pediatric population than in adults. In pediatric patients aged 2 to 5 years who received 5 mg of cetirizine, the mean Cmax was 660 ng/mL. Based on cross-study comparisons, the weight-normalized apparent total body clearance was 81 to 111% greater and the elimination half-life was 33 to 41% shorter in this pediatric population than in adults. In pediatric patients aged 6 to 23 months who received a single dose of 0.25 mg/kg cetirizine oral solution (mean dose 2.3 mg), the mean Cmax was 390 ng/mL. Based on cross-study comparisons, the weight-normalized, apparent total body clearance was 304% greater and the elimination half-life was 63% shorter in this pediatric population compared to adults. The average AUC(0–t) in children 6 months to <2 years of age receiving the maximum dose of cetirizine solution (2.5 mg twice a day) is expected to be two-fold higher than that observed in adults receiving a dose of 10 mg cetirizine tablets once a day.
Geriatric Patients
Following a single, 10-mg oral dose, the elimination half-life was prolonged by 50% and the apparent total body clearance was 40% lower in 16 geriatric subjects with a mean age of 77 years compared to 14 adult subjects with a mean age of 53 years. The decrease in cetirizine clearance in these elderly volunteers may be related to decreased renal function.
A dosing adjustment may be necessary in patients 77 years of age and older (see DOSAGE AND ADMINISTRATION).
Effect of Gender
The effect of gender on cetirizine pharmacokinetics has not been adequately studied.
Effect of Race
No race-related differences in the kinetics of cetirizine have been observed.
Renal Impairment
The kinetics of cetirizine were studied following multiple, oral, 10-mg daily doses of cetirizine for 7 days in 7 normal volunteers (creatinine clearance 89–128 mL/min), 8 patients with mild renal function impairment (creatinine clearance 42–77 mL/min) and 7 patients with moderate renal function impairment (creatinine clearance 11–31 mL/min). The pharmacokinetics of cetirizine were similar in patients with mild impairment and normal volunteers. Moderately impaired patients had a 3-fold increase in half-life and a 70% decrease in clearance compared to normal volunteers.
Patients on hemodialysis (n=5) given a single, 10-mg dose of cetirizine had a 3-fold increase in half-life and a 70% decrease in clearance compared to normal volunteers. Less than 10% of the administered dose was removed during the single dialysis session.
Dosing adjustment is necessary in patients with moderate or severe renal impairment and in patients on dialysis (see DOSAGE AND ADMINISTRATION).
Hepatic Impairment
Sixteen patients with chronic liver diseases (hepatocellular, cholestatic, and biliary cirrhosis), given 10 or 20 mg of cetirizine as a single, oral dose had a 50% increase in half-life along with a corresponding 40% decrease in clearance compared to 16 healthy subjects.
Dosing adjustment may be necessary in patients with hepatic impairment (see DOSAGE AND ADMINISTRATION).
Pharmacodynamics
Studies in 69 adult normal volunteers (aged 20 to 61 years) showed that ZYRTEC at doses of 5 and 10 mg strongly inhibited the skin wheal and flare caused by the intradermal injection of histamine. The onset of this activity after a single 10-mg dose occurred within 20 minutes in 50% of subjects and within one hour in 95% of subjects; this activity persisted for at least 24 hours. ZYRTEC at doses of 5 and 10 mg also strongly inhibited the wheal and flare caused by intradermal injection of histamine in 19 pediatric volunteers (aged 5 to 12 years) and the activity persisted for at least 24 hours. In a 35-day study in children aged 5 to 12, no tolerance to the antihistaminic (suppression of wheal and flare response) effects of ZYRTEC was found. In 10 infants 7 to 25 months of age who received 4 to 9 days of cetirizine in an oral solution (0.25 mg/kg bid), there was a 90% inhibition of histamine-induced (10 mg/mL) cutaneous wheal and 87% inhibition of the flare 12 hours after administration of the last dose. The clinical relevance of this suppression of histamine-induced wheal and flare response on skin testing is unknown.
The effects of intradermal injection of various other mediators or histamine releasers were also inhibited by cetirizine, as was response to a cold challenge in patients with cold-induced urticaria. In mildly asthmatic subjects, ZYRTEC at 5 to 20 mg blocked bronchoconstriction due to nebulized histamine, with virtually total blockade after a 20-mg dose. In studies conducted for up to 12 hours following cutaneous antigen challenge, the late phase recruitment of eosinophils, neutrophils and basophils, components of the allergic inflammatory response, was inhibited by ZYRTEC at a dose of 20 mg.
In four clinical studies in healthy adult males, no clinically significant mean increases in QTc were observed in ZYRTEC treated subjects. In the first study, a placebo-controlled crossover trial, ZYRTEC was given at doses up to 60 mg per day, 6 times the maximum clinical dose, for 1 week, and no significant mean QTc prolongation occurred. In the second study, a crossover trial, ZYRTEC 20 mg and erythromycin (500 mg every 8 hours) were given alone and in combination. There was no significant effect on QTc with the combination or with ZYRTEC alone. In the third trial, also a crossover study, ZYRTEC 20 mg and ketoconazole (400 mg per day) were given alone and in combination. ZYRTEC caused a mean increase in QTc of 9.1 msec from baseline after 10 days of therapy. Ketoconazole also increased QTc by 8.3 msec. The combination caused an increase of 17.4 msec, equal to the sum of the individual effects. Thus, there was no significant drug interaction on QTc with the combination of ZYRTEC and ketoconazole. In the fourth study, a placebo-controlled parallel trial, ZYRTEC 20 mg was given alone or in combination with azithromycin (500 mg as a single dose on the first day followed by 250 mg once daily). There was no significant increase in QTc with ZYRTEC 20 mg alone or in combination with azithromycin.
In a four-week clinical trial in pediatric patients aged 6 to 11 years, results of randomly obtained ECG measurements before treatment and after 2 weeks of treatment showed that ZYRTEC 5 or 10 mg did not increase QTc versus placebo. In a one week clinical trial (N=86) of ZYRTEC syrup (0.25 mg/kg bid) compared with placebo in pediatric patients 6 to 11 months of age, ECG measurements taken within 3 hours of the last dose did not show any ECG abnormalities or increases in QTc interval in either group compared to baseline assessments. Data from other studies where ZYRTEC was administered to patients 6–23 months of age were consistent with the findings in this study.
The effects of ZYRTEC on the QTc interval at doses higher than 10 mg have not been studied in children less than 12 years of age.
In a six-week, placebo-controlled study of 186 patients (aged 12 to 64 years) with allergic rhinitis and mild to moderate asthma, ZYRTEC 10 mg once daily improved rhinitis symptoms and did not alter pulmonary function. In a two-week, placebo-controlled clinical trial, a subset analysis of 65 pediatric (aged 6 to 11 years) allergic rhinitis patients with asthma showed ZYRTEC did not alter pulmonary function. These studies support the safety of administering ZYRTEC to pediatric and adult allergic rhinitis patients with mild to moderate asthma.
Clinical Studies
Nine multicenter, randomized, double-blind, clinical trials comparing cetirizine 5 to 20 mg to placebo in patients 12 years and older with seasonal or perennial allergic rhinitis were conducted in the United States. Five of these showed significant reductions in symptoms of allergic rhinitis, 3 in seasonal allergic rhinitis (1 to 4 weeks in duration) and 2 in perennial allergic rhinitis for up to 8 weeks in duration. Two 4-week multicenter, randomized, double-blind, clinical trials comparing cetirizine 5 to 20 mg to placebo in patients with chronic idiopathic urticaria were also conducted and showed significant improvement in symptoms of chronic idiopathic urticaria. In general, the 10-mg dose was more effective than the 5-mg dose and the 20-mg dose gave no added effect. Some of these trials included pediatric patients aged 12 to 16 years. In addition, four multicenter, randomized, placebo-controlled, double-blind 2–4 week trials in 534 pediatric patients aged 6 to 11 years with seasonal allergic rhinitis were conducted in the United States at doses up to 10 mg.
Indications and Usage for Zyrtec Tablets
Seasonal Allergic Rhinitis
ZYRTEC is indicated for the relief of symptoms associated with seasonal allergic rhinitis due to allergens such as ragweed, grass and tree pollens in adults and children 2 years of age and older. Symptoms treated effectively include sneezing, rhinorrhea, nasal pruritus, ocular pruritus, tearing, and redness of the eyes.
Perennial Allergic Rhinitis
ZYRTEC is indicated for the relief of symptoms associated with perennial allergic rhinitis due to allergens such as dust mites, animal dander and molds in adults and children 6 months of age and older. Symptoms treated effectively include sneezing, rhinorrhea, postnasal discharge, nasal pruritus, ocular pruritus, and tearing.
Chronic Urticaria
ZYRTEC is indicated for the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 months of age and older. It significantly reduces the occurrence, severity, and duration of hives and significantly reduces pruritus.
Contraindications
ZYRTEC is contraindicated in those patients with a known hypersensitivity to it or any of its ingredients or hydroxyzine.
Precautions
Activities Requiring Mental Alertness
In clinical trials, the occurrence of somnolence has been reported in some patients taking ZYRTEC; due caution should therefore be exercised when driving a car or operating potentially dangerous machinery. Concurrent use of ZYRTEC with alcohol or other CNS depressants should be avoided because additional reductions in alertness and additional impairment of CNS performance may occur.
Drug-Drug Interactions
No clinically significant drug interactions have been found with theophylline at a low dose, azithromycin, pseudoephedrine, ketoconazole, or erythromycin. There was a small decrease in the clearance of cetirizine caused by a 400-mg dose of theophylline; it is possible that larger theophylline doses could have a greater effect.
Carcinogenesis, Mutagenesis and Impairment of Fertility
In a 2-year carcinogenicity study in rats, cetirizine was not carcinogenic at dietary doses up to 20 mg/kg (approximately 15 times the maximum recommended daily oral dose in adults on a mg/m2 basis, or approximately 7 times the maximum recommended daily oral dose in infants on a mg/m2 basis). In a 2-year carcinogenicity study in mice, cetirizine caused an increased incidence of benign liver tumors in males at a dietary dose of 16 mg/kg (approximately 6 times the maximum recommended daily oral dose in adults on a mg/m2 basis, or approximately 3 times the maximum recommended daily oral dose in infants on a mg/m2 basis). No increase in the incidence of liver tumors was observed in mice at a dietary dose of 4 mg/kg (approximately 2 times the maximum recommended daily oral dose in adults on a mg/m2 basis, or approximately equivalent to the maximum recommended daily oral dose in infants on a mg/m2 basis). The clinical significance of these findings during long-term use of ZYRTEC is not known.
Cetirizine was not mutagenic in the Ames test, and not clastogenic in the human lymphocyte assay, the mouse lymphoma assay, and in vivo micronucleus test in rats.
In a fertility and general reproductive performance study in mice, cetirizine did not impair fertility at an oral dose of 64 mg/kg (approximately 25 times the maximum recommended daily oral dose in adults on a mg/m2 basis).
Pregnancy Category B
In mice, rats, and rabbits, cetirizine was not teratogenic at oral doses up to 96, 225, and 135 mg/kg, respectively (approximately 40, 180 and 220 times the maximum recommended daily oral dose in adults on a mg/m2 basis). There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, ZYRTEC should be used during pregnancy only if clearly needed.
Nursing Mothers
In mice, cetirizine caused retarded pup weight gain during lactation at an oral dose in dams of 96 mg/kg (approximately 40 times the maximum recommended daily oral dose in adults on a mg/m2 basis). Studies in beagle dogs indicated that approximately 3% of the dose was excreted in milk. Cetirizine has been reported to be excreted in human breast milk. Because many drugs are excreted in human milk, use of ZYRTEC in nursing mothers is not recommended.
Geriatric Use
Of the total number of patients in clinical studies of ZYRTEC, 186 patients were 65 years and older, and 39 patients were 75 years and older. No overall differences in safety were observed between these patients and younger patients, but greater sensitivity of some older individuals cannot be ruled out. With regard to efficacy, clinical studies of ZYRTEC for each approved indication did not include sufficient numbers of patients aged 65 years and older to determine whether they respond differently than younger patients.
ZYRTEC is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. (See Geriatric Patients and Renal Impairment subsections in CLINICAL PHARMACOLOGY .)
Pediatric Use
The safety of ZYRTEC has been demonstrated in pediatric patients aged 6 months to 11 years. The safety of ZYRTEC, at daily doses of 5 or 10 mg, has been demonstrated in 376 pediatric patients aged 6 to 11 years in placebo-controlled trials lasting up to four weeks and in 254 patients in a non-placebo-controlled 12-week trial. The safety of cetirizine has been demonstrated in 168 patients aged 2 to 5 years in placebo-controlled trials of up to 4 weeks duration. On a mg/kg basis, most of the 168 patients received between 0.2 and 0.4 mg/kg of cetirizine HCl. The safety of cetirizine in 399 patients aged 12 to 24 months has been demonstrated in a placebo-controlled 18-month trial, in which the average dose was 0.25 mg/kg bid, corresponding to a range of 4 to 11 mg/day. The safety of ZYRTEC syrup has been demonstrated in 42 patients aged 6 to 11 months in a placebo-controlled 7-day trial. The prescribed dose was 0.25 mg/kg bid, which corresponded to a mean of 4.5 mg/day, with a range of 3.4 to 6.2 mg/day.
The effectiveness of ZYRTEC for the treatment of allergic rhinitis and chronic idiopathic urticaria in pediatric patients aged 6 months to 11 years is based on an extrapolation of the demonstrated efficacy of ZYRTEC in adults with these conditions and the likelihood that the disease course, pathophysiology and the drug’s effect are substantially similar between these two populations. Efficacy is extrapolated down to 6 months of age for perennial allergic rhinitis and down to 2 years of age for seasonal allergic rhinitis because these diseases are thought to occur down to these ages in children. The recommended doses for the pediatric population are based on cross-study comparisons of the pharmacokinetics and pharmacodynamics of cetirizine in adult and pediatric subjects and on the safety profile of cetirizine in both adult and pediatric patients at doses equal to or higher than the recommended doses. The cetirizine AUC and Cmax in pediatric subjects aged 6 to 23 months who received a mean of 2.3 mg in a single dose, and in subjects aged 2 to 5 years who received a single dose of 5 mg of cetirizine syrup and in pediatric subjects aged 6 to 11 years who received a single dose of 10 mg of cetirizine syrup were estimated to be intermediate between that observed in adults who received a single dose of 10 mg of cetirizine tablets and those who received a single dose of 20 mg of cetirizine tablets.
The safety and effectiveness of cetirizine in pediatric patients under the age of 6 months have not been established.
Adverse Reactions
Controlled and uncontrolled clinical trials conducted in the United States and Canada included more than 6000 patients aged 12 years and older, with more than 3900 receiving ZYRTEC at doses of 5 to 20 mg per day. The duration of treatment ranged from 1 week to 6 months, with a mean exposure of 30 days.
Most adverse reactions reported during therapy with ZYRTEC were mild or moderate. In placebo-controlled trials, the incidence of discontinuations due to adverse reactions in patients receiving ZYRTEC 5 or 10 mg was not significantly different from placebo (2.9% vs. 2.4%, respectively).
The most common adverse reaction in patients aged 12 years and older that occurred more frequently on ZYRTEC than placebo was somnolence. The incidence of somnolence associated with ZYRTEC was dose related, 6% in placebo, 11% at 5 mg and 14% at 10 mg. Discontinuations due to somnolence for ZYRTEC were uncommon (1.0% on ZYRTEC vs. 0.6% on placebo). Fatigue and dry mouth also appeared to be treatment-related adverse reactions. There were no differences by age, race, gender or by body weight with regard to the incidence of adverse reactions.
Table 1 lists adverse experiences in patients aged 12 years and older which were reported for ZYRTEC 5 and 10 mg in controlled clinical trials in the United States and that were more common with ZYRTEC than placebo.
| Adverse Experience |
ZYRTEC (N=2034) |
Placebo (N=1612) |
|---|---|---|
| Somnolence | 13.7 | 6.3 |
| Fatigue | 5.9 | 2.6 |
| Dry Mouth | 5.0 | 2.3 |
| Pharyngitis | 2.0 | 1.9 |
| Dizziness | 2.0 | 1.2 |
In addition, headache and nausea occurred in more than 2% of the patients, but were more common in placebo patients.
Pediatric studies were also conducted with ZYRTEC. More than 1300 pediatric patients aged 6 to 11 years with more than 900 treated with ZYRTEC at doses of 1.25 to 10 mg per day were included in controlled and uncontrolled clinical trials conducted in the United States. The duration of treatment ranged from 2 to 12 weeks. Placebo-controlled trials up to 4 weeks duration included 168 pediatric patients aged 2 to 5 years who received cetirizine, the majority of whom received single daily doses of 5 mg. A placebo-controlled trial 18 months in duration included 399 patients aged 12 to 24 months treated with cetirizine (0.25 mg/kg bid), and another placebo-controlled trial of 7 days duration included 42 patients aged 6 to 11 months who were treated with cetirizine (0.25 mg/kg bid).
The majority of adverse reactions reported in pediatric patients aged 2 to 11 years with ZYRTEC were mild or moderate. In placebo-controlled trials, the incidence of discontinuations due to adverse reactions in pediatric patients receiving up to 10 mg of ZYRTEC was uncommon (0.4% on ZYRTEC vs. 1.0% on placebo).
Table 2 lists adverse experiences which were reported for ZYRTEC 5 and 10 mg in pediatric patients aged 6 to 11 years in placebo-controlled clinical trials in the United States and were more common with ZYRTEC than placebo. Of these, abdominal pain was considered treatment-related and somnolence appeared to be dose-related, 1.3% in placebo, 1.9% at 5 mg and 4.2% at 10 mg. The adverse experiences reported in pediatric patients aged 2 to 5 years in placebo-controlled trials were qualitatively similar in nature and generally similar in frequency to those reported in trials with children aged 6 to 11 years.
In the placebo-controlled trials of pediatric patients 6 to 24 months of age, the incidences of adverse experiences were similar in the cetirizine and placebo treatment groups in each study. Somnolence occurred with essentially the same frequency in patients who received cetirizine and patients who received placebo. In a study of 1 week duration in children 6–11 months of age, patients who received cetirizine exhibited greater irritability/fussiness than patients on placebo. In a study of 18 months duration in patients 12 months and older, insomnia occurred more frequently in patients who received cetirizine compared to patients who received placebo (9.0% v. 5.3%). In those patients who received 5 mg or more per day of cetirizine as compared to patients who received placebo, fatigue (3.6% v. 1.3%) and malaise (3.6% v. 1.8%) occurred more frequently.
| ZYRTEC | |||
|---|---|---|---|
| Adverse Experiences | Placebo (N=309) |
5 mg (N=161) |
10 mg (N=215) |
| Headache | 12.3% | 11.0% | 14.0% |
| Pharyngitis | 2.9% | 6.2% | 2.8% |
| Abdominal pain | 1.9% | 4.4% | 5.6% |
| Coughing | 3.9% | 4.4% | 2.8% |
| Somnolence | 1.3% | 1.9% | 4.2% |
| Diarrhea | 1.3% | 3.1% | 1.9% |
| Epistaxis | 2.9% | 3.7% | 1.9% |
| Bronchospasm | 1.9% | 3.1% | 1.9% |
| Nausea | 1.9% | 1.9% | 2.8% |
| Vomiting | 1.0% | 2.5% | 2.3% |
The following events were observed infrequently (less than 2%), in either 3982 adults and children 12 years and older or in 659 pediatric patients aged 6 to 11 years who received ZYRTEC in U.S. trials, including an open adult study of six months duration. A causal relationship of these infrequent events with ZYRTEC administration has not been established.
Autonomic Nervous System: anorexia, flushing, increased salivation, urinary retention.
Cardiovascular: cardiac failure, hypertension, palpitation, tachycardia.
Central and Peripheral Nervous Systems: abnormal coordination, ataxia, confusion, dysphonia, hyperesthesia, hyperkinesia, hypertonia, hypoesthesia, leg cramps, migraine, myelitis, paralysis, paresthesia, ptosis, syncope, tremor, twitching, vertigo, visual field defect.
Gastrointestinal: abnormal hepatic function, aggravated tooth caries, constipation, dyspepsia, eructation, flatulence, gastritis, hemorrhoids, increased appetite, melena, rectal hemorrhage, stomatitis including ulcerative stomatitis, tongue discoloration, tongue edema.
Genitourinary: cystitis, dysuria, hematuria, micturition frequency, polyuria, urinary incontinence, urinary tract infection.
Hearing and Vestibular: deafness, earache, ototoxicity, tinnitus.
Metabolic/Nutritional: dehydration, diabetes mellitus, thirst.
Musculoskeletal: arthralgia, arthritis, arthrosis, muscle weakness, myalgia.
Psychiatric: abnormal thinking, agitation, amnesia, anxiety, decreased libido, depersonalization, depression, emotional lability, euphoria, impaired concentration, insomnia, nervousness, paroniria, sleep disorder.
Respiratory System: bronchitis, dyspnea, hyperventilation, increased sputum, pneumonia, respiratory disorder, rhinitis, sinusitis, upper respiratory tract infection.
Reproductive: dysmenorrhea, female breast pain, intermenstrual bleeding, leukorrhea, menorrhagia, vaginitis.
Reticuloendothelial: lymphadenopathy.
Skin: acne, alopecia, angioedema, bullous eruption, dermatitis, dry skin, eczema, erythematous rash, furunculosis, hyperkeratosis, hypertrichosis, increased sweating, maculopapular rash, photosensitivity reaction, photosensitivity toxic reaction, pruritus, purpura, rash, seborrhea, skin disorder, skin nodule, urticaria.
Special Senses: parosmia, taste loss, taste perversion.
Vision: blindness, conjunctivitis, eye pain, glaucoma, loss of accommodation, ocular hemorrhage, xerophthalmia.
Body as a Whole: accidental injury, asthenia, back pain, chest pain, enlarged abdomen, face edema, fever, generalized edema, hot flashes, increased weight, leg edema, malaise, nasal polyp, pain, pallor, periorbital edema, peripheral edema, rigors.
Occasional instances of transient, reversible hepatic transaminase elevations have occurred during cetirizine therapy. Hepatitis with significant transaminase elevation and elevated bilirubin in association with the use of ZYRTEC has been reported.
Post-Marketing Experience
In the post-marketing period, the following additional rare, but potentially severe adverse events have been reported: aggressive reaction, anaphylaxis, cholestasis, convulsions, glomerulonephritis, hallucinations, hemolytic anemia, hepatitis, orofacial dyskinesia, severe hypotension, stillbirth, suicidal ideation, suicide and thrombocytopenia.
Drug Abuse and Dependence
There is no information to indicate that abuse or dependency occurs with ZYRTEC.
Overdosage
Overdosage has been reported with ZYRTEC. In one adult patient who took 150 mg of ZYRTEC, the patient was somnolent but did not display any other clinical signs or abnormal blood chemistry or hematology results. In an 18 month old pediatric patient who took an overdose of ZYRTEC (approximately 180 mg), restlessness and irritability were observed initially; this was followed by drowsiness. Should overdose occur, treatment should be symptomatic or supportive, taking into account any concomitantly ingested medications. There is no known specific antidote to ZYRTEC. ZYRTEC is not effectively removed by dialysis, and dialysis will be ineffective unless a dialyzable agent has been concomitantly ingested. The acute minimal lethal oral doses were 237 mg/kg in mice (approximately 95 times the maximum recommended daily oral dose in adults on a mg/m2 basis, or approximately 40 times the maximum recommended daily oral dose in infants on a mg/m2 basis) and 562 mg/kg in rats (approximately 460 times the maximum recommended daily oral dose in adults on a mg/m2 basis, or approximately 190 times the maximum recommended daily oral dose in infants on a mg/m2 basis). In rodents, the target of acute toxicity was the central nervous system, and the target of multiple-dose toxicity was the liver.
Zyrtec Tablets Dosage and Administration
ZYRTEC can be taken without regard to food consumption. ZYRTEC is available as 5 mg and 10 mg tablets, 1 mg/mL syrup, and 5 mg and 10 mg chewable tablets which can be taken with or without water.
Adults and Children 12 Years and Older
The recommended initial dose of ZYRTEC is 5 mg or 10 mg per day in adults and children 12 years and older, depending on symptom severity. Most patients in clinical trials started at 10 mg. ZYRTEC is given as a single daily dose. The time of administration may be varied to suit individual patient needs.
Children 6 to 11 Years
The recommended initial dose of ZYRTEC in children aged 6 to 11 years is 5 mg or 10 mg once daily depending on symptom severity. The time of administration may be varied to suit individual patient needs.
Children 2 to 5 Years
The recommended initial dose of ZYRTEC in children aged 2 to 5 years is 2.5 mg (½ teaspoon) syrup once daily. The dosage in this age group can be increased to a maximum dose of 5 mg per day given as 1 teaspoon syrup once a day or one ½ teaspoon syrup given every 12 hours, or one 5 mg chewable tablet once a day.
Children 6 months to <2 years
The recommended dose of ZYRTEC syrup in children 6 months to 23 months of age is 2.5 mg (½ teaspoon) once daily. The dose in children 12 to 23 months of age can be increased to a maximum dose of 5 mg per day, given as ½ teaspoon (2.5 mg) every 12 hours. Syrup is recommended for children under the age of 2 years.
Dose Adjustment for Renal and Hepatic Impairment
In patients 12 years of age and older with decreased renal function (creatinine clearance 11–31 mL/min), patients on hemodialysis (creatinine clearance less than 7 mL/min), and in hepatically impaired patients, a dose of 5 mg once daily is recommended. Similarly, pediatric patients aged 6 to 11 years with impaired renal or hepatic function should use the lower recommended dose. Because of the difficulty in reliably administering doses of less than 2.5 mg (½ teaspoon) of ZYRTEC syrup and in the absence of pharmacokinetic and safety information for cetirizine in children below the age of 6 years with impaired renal or hepatic function, its use in this impaired patient population is not recommended.
Dose Adjustment for Geriatric Patients
In patients 77 years of age and older, a dose of 5 mg once daily is recommended.
How is Zyrtec Tablets Supplied
Zyrtec Tablets are white, film-coated, rounded-off rectangular shaped containing 5 mg or 10 mg cetirizine hydrochloride.
5 mg tablets are engraved with “ZYRTEC” on one side and “5″ on the other.
Bottles of 100: NDC 0069-0732-66
10 mg tablets are engraved with “ZYRTEC” on one side and “10″ on the other.
Bottles of 100: NDC 0069-0731-66
STORAGE: Store at 20–25°C (68–77°F); excursions permitted to 15–30°C (59–86°F) [see USP Controlled Room Temperature].
ZYRTEC chewable tablets are purple round tablets containing 5 mg or 10 mg cetirizine hydrochloride. The tablets are packaged in blister cards as follows:
5 mg tablets are engraved with “ZYRTEC C5″ on one side.
Boxes of 3 (Blister Cards of 10) NDC 0069-1440-03
10 mg tablets are engraved with “ZYRTEC C10″ on one side.
Boxes of 3 (Blister Cards of 10) NDC 0069-1450-03
STORAGE: Store at 20–25°C (68–77°F); excursions permitted to 15–30°C (59–86°F) [see USP Controlled Room Temperature].
ZYRTEC syrup is colorless to slightly yellow with a banana-grape flavor. Each teaspoon (5 mL) contains 5 mg cetirizine hydrochloride. ZYRTEC syrup is supplied as follows:
120 mL amber glass bottles NDC 0069-5530-47
480 mL amber glass bottles NDC 0069-5530-93
STORAGE: Store at 20–25°C (68–77°F); excursions permitted to 15–30°C (59–86°F) [see USP Controlled Room Temperature]; or Store refrigerated, 2–8°C (36–46°F).
Cetirizine is licensed from UCB, Inc.
Rx only

Marketed by
UCB, Inc.
Smyrna, GA 30080
LAB-0037-7.0
May 2006
| ZYRTEC cetirizine hydrochloride tablet, film coated |
||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||
| ZYRTEC cetirizine hydrochloride tablet, film coated |
||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||
| ZYRTEC cetirizine hydrochloride tablet, chewable |
|||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
| ZYRTEC cetirizine hydrochloride tablet, chewable |
|||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
| ZYRTEC cetirizine hydrochloride syrup |
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
Revised: 10/2006Pfizer Labs
Zyrtec Capsule
30/06/10
Generic Name: cetirizine hydrochloride
Dosage Form: capsule, liquid filled
Drug Facts
Active ingredient (in each capsule)
Cetirizine HCl 10 mg
Purpose
Antihistamine
Uses
temporarily relieves these symptoms due to hay fever or other upper respiratory allergies:
- runny nose
- sneezing
- itchy, watery eyes
- itching of the nose or throat
Warnings
Do not use if you have ever had an allergic reaction to this product or any of its ingredients or to an antihistamine containing hydroxyzine.
Ask a doctor before use if you have liver or kidney disease. Your doctor should determine if you need a different dose.
Ask a doctor or pharmacist before use if you are taking tranquilizers or sedatives.
When using this product
- drowsiness may occur
- avoid alcoholic drinks
- alcohol, sedatives, and tranquilizers may increase drowsiness
- be careful when driving a motor vehicle or operating machinery
Stop use and ask a doctor if an allergic reaction to this product occurs. Seek medical help right away.
If pregnant or breast-feeding:
- if breast-feeding: not recommended
- if pregnant: ask a health professional before use.
Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away. (1-800-222-1222)
Directions
| adults and children 6 years and over | one 10 mg capsule once daily; do not take more than one 10 mg capsule in 24 hours. A 5 mg product may be appropriate for less severe symptoms. |
| adults 65 years and over | ask a doctor |
| children under 6 years of age | ask a doctor |
| consumers with liver or kidney disease | ask a doctor |
Other information
- store at 20° – 25°C (68° – 77°F)
- avoid high humidity and excessive heat above 40°C (104°F)
- protect from light
- do not use if foil inner seal printed with “Safety Seal®” is broken or missing
Inactive ingredients
gelatin, glycerin, mannitol, pharmaceutical ink, polyethylene glycol 400, purified water, sodium hydroxide, sorbitan, sorbitol
Questions or comments?
call 1-800-343-7805
PRINCIPAL DISPLAY PANEL
Original Prescription Strength
NDC 50580-779-40
ZYRTEC ®
ALLERGY
NEW
LIQUID GELS
Cetirizine HCl/
antihistamine
10 mg capsules
INDOOR + OUTDOOR
ALLERGIES
LIQUID
GELS
24
HOUR
RELIEF OF
- Sneezing
- Runny Nose
- Itchy, Watery Eyes
- Itchy Throat or Nose
40
LIQUID GELS*
*LIQUID-FILLED CAPSULES
10 mg each

| ZYRTEC cetirizine hydrochloride capsule, liquid filled |
|||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||
| Marketing Information | |||
| Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
| NDA | NDA022429 | 02/08/2010 | |
| Labeler - McNeil Consumer Healthcare Div McNeil-PPC, Inc (878046358) |
Revised: 12/2009McNeil Consumer Healthcare Div McNeil-PPC, Inc
